This trial is active, not recruiting.

Condition lupus
Treatment prasterone (gl701)
Phase phase 3
Sponsor Genelabs Technologies
Start date December 2002
End date August 2004
Trial size 155 participants
Trial identifier NCT00053560, GL02-01


The purpose of this clinical trial is to study the effects of GL701 on bone mineral density in women with active systemic lupus erythematosus (SLE) who are also receiving treatment with glucocorticoids (e.g., prednisone).

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double-blind
Primary purpose prevention

Eligibility Criteria

Female participants at least 18 years old.

INCLUSION CRITERIA - Women at least 18 years of age. - Meet ACR criteria for diagnosis of SLE. - Concomitant treatment with prednisone at a dose of ≥5 mg/day over the last 30 days prior to Screening visit. - Cumulative history of oral glucocorticoid use for at least 6 months over the last year prior to the Screening Visit (the 6 months do not have to be consecutive). - Patient has lumbar spine and proximal femur anatomy suitable for measurement by DXA with at least 3 evaluable vertebrae from L1 to L4. - SLEDAI ≥3 at the Qualifying Visit. - Women of child-bearing potential must have a negative serum pregnancy test (at the Screening Visit) and agree to use a reliable form of birth control while participating in the study. - Patient is fully ambulatory. - Patient has read and signed an Informed Consent Form. EXCLUSION CRITERIA - History of breast cancer or malignancy of the reproductive tract organs. - History of any other cancers unless no evidence of disease for 5 years. - History of endometrial hyperplasia. - End stage renal disease or receiving hemodialysis treatment. - Any disease or condition that would preclude the accurate measurement of bone mineral density of the lumbar spine or proximal femur by dual X-ray absorptiometry. - A T-score of less than or equal to - 2.5 of the L-spine or proximal femur at Screening DXA assessment. - Unstable cardiac disease. - Conditions causing bone loss such as hyperparathyroidism, Cushing's disease, thyrotoxicosis, chronic diarrheal state or malabsorption, renal tubular acidosis, or anorexia nervosa. - Significant hepatic disease (i.e., cirrhosis). - Body mass index > 35 kg/m2 or weight >300 lbs. - Patients who are pregnant or breast feeding. - Patients who require glucocorticoids by an alternate day dosing schedule. - Known hypersensitivity to DHEA, or the inactive ingredients used in the GL701 formulation (cornstarch, lactose, magnesium stearate). - Known medical contraindication or hypersensitivity to Calcium/Vitamin D. - Participation in any prior DHEA or GL701 study. - Use of investigational agents within 30 days of the Screening Visit or 10 half-lives of the agent. - Any condition which in the Investigator's or Sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation (e.g., alcoholism, drug addiction, acute withdrawal from chemical dependency, psychiatric disease). - The patient is taking or has taken one of the medications listed below: ANTIRESORPTIVES: - Use of calcitonin within 30 days prior to Screening Visit. - Fluorides > 1 mg/day at any time prior to the study. - Strontium at pharmacologic dose at any time. BISPHOSPHONATE USE as follows: - Any use within 90 days prior to the Screening Visit. - ≥ 2 weeks of use in the last year prior to the Screening Visit. - ≥ 3 months of use in the last 2 years prior to the Screening Visit. - ≥ 1 intravenous dose over the last 2 years prior to the Screening Visit. - ≥ 6 months of life-time exposure prior to the Screening Visit. ESTROGENIC STEROIDS (Except for oral contraceptives): - Estrogenic steroids (HRT) within 60 days of the Screening Visit. - Selective estrogen receptor modulator (raloxifene) within 60 days of the Screening Visit. OTHER HORMONES: - Parathyroid hormone (PTH) within six months of the Screening Visit. - Use of any androgens, including prescription or nutritional supplement DHEA, within 30 days of the Screening Visit.

Additional Information

Official title A Randomized, Double-Blind, Multi-Center, Placebo- Controlled Study to Assess Prevention of Bone Loss by Treatment With GL701 (Prestara) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids
Trial information was received from ClinicalTrials.gov and was last updated in December 2007.
Information provided to ClinicalTrials.gov by Genelabs Technologies.